Skip to main content
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Clinical Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • Quality Improvement Sucess Stories
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
  • Advertising
  • Reprints/Reuse
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Instructions for Authors
    • ADA Journal Policies
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • Quality Improvement Sucess Stories
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
  • Advertising
  • Reprints/Reuse
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Instructions for Authors
    • ADA Journal Policies
Departments

Gvoke HypoPen: An Auto-Injector Containing an Innovative, Liquid-Stable Glucagon Formulation for Use in Severe Acute Hypoglycemia

  1. Damianne Brand-Eubanks
  1. Department of Pharmacotherapy, Yakima Extension, Washington State University College of Pharmacy and Pharmaceutical Sciences, Yakima, WA
  1. Corresponding author: Damianne Brand-Eubanks, dbrand{at}wsu.edu
Clinical Diabetes 2019 Oct; 37(4): 393-394. https://doi.org/10.2337/cd19-0040
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Introduction

The use of insulin to decrease complications associated with diabetes currently focuses on attempts to control elevated glucose levels. This has often been balanced with a calculated risk potential for over-treatment and resultant hypoglycemia. This subsequent hypoglycemia can have a greater effect on morbidity and mortality for patients with type 1 diabetes, who are reliant on exogenous insulin, and extreme hypoglycemic events are directly associated with substantial overall health care costs (1). Current therapy for acute, severe hypoglycemia includes a glucagon emergency kit (GEK), which is effective when used correctly. However, training on how to appropriately assemble the GEK is rare, and administration of emergency glucagon can be complicated for the inexperienced.

Glucagon, a peptide hormone normally produced endogenously in the pancreas, acts as an agonist at the glucagon receptor, initiating a pathway resulting in the conversion of glycogen in the liver to the more accessible form of glucose that can be released into the blood. Exogenous glucagon is currently available in a powder that must be reconstituted in solution immediately before intramuscular or intravenous delivery due to its instability in solution (2,3). Xeris Pharmaceuticals has submitted new drug applications to both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for a new glucagon formulation addressing the historical complication of instability in solution. The company proposes a novel, ready-to-use, liquid-stable glucagon in an auto-injector that does not require mixing before use.

Indications

On its new drug application (NDA), the manufacturer is seeking an indication for the treatment of severe acute hypoglycemia in patients with diabetes treated with insulin. The company is also seeking an orphan drug status designation with indications for congenital hyperinsulinemic hypoglycemia and post–bariatric surgery hypoglycemia.

Mechanism of Action

The Gvoke HypoPen subcutaneously administers a liquid-stable but nonaqueous glucagon formulation that contains a human recombinant DNA–derived amino acid polypeptide similar to that used in the currently available GEK. Glucagon is an agonist for glycogen receptors, initiating the conversion of stored glycogen into glucose and thereby increasing the concentration of glucose in the blood.

The glucagon formulation is packaged in a ready-to-deliver auto-injector similar to the epinephrine rescue pens used for anaphylaxis. A freeze-dried powder that contains glucagon; trehalose, hydroxyethyl, or a similar starch with a glycine buffer (maintaining a pH of 2.0–3.5); a surfactant; an antioxidant; and a chelating agent is combined with a polar aprotic liquid comprising triacetin, thereby preventing the aggregation and fibrillation of the glucagon that is normally propagated by aqueous solutions. This process creates a low-volume, highly concentrated solution (4). The auto-injector will be available in two premeasured doses: a 0.5 mg/0.1 mL dose for pediatric administration and a 1 mg/0.2 mL dose for adolescent and adult administration (5).

Potential Advantages

The ease of use of an auto-injector and a decrease in the number of steps currently required to reconstitute glucagon powder for injection are meaningful advantages. The auto-injector was shown to have a significantly higher success rate in delivering a full glucagon dose during simulated emergencies with both trained and untrained users (6). The glucagon auto-injector also more quickly resolved global hypoglycemia symptoms compared to the current GEK (6).

This novel delivery system requires only two simple steps. First, users must remove the cap from the pen. Second, they must press the auto-injector against the skin, holding for 5 seconds. Upon contact with the skin, the auto-injector delivers a rescue dose of glucagon (6). No calibration of the dose is required (6).

Additionally, with this device, there is no exposed needle. The needle is protected by a sheath guard, and the needle itself retracts into the body of the auto-injector after administration, making unintentional needle sticks less likely. Due to the low volume of the dose, there is less associated injection-site pain than compared to the GEK (4). Finally, studies indicate that the medication in this device can be stored at room temperature for 2 years with no refrigeration required at any time (4).

Potential Disadvantages

This nonaqueous solution is delivered subcutaneously, so it does not decrease the potential side effects of nausea and vomiting associated with parenterally delivered glucagon compared to the GEK (6).

Cost

A link between more prompt treatment and length of hospital stay has been established through historical data associated with the GEK, and ease of use may lead to a decrease in overall health care costs (7). However, because this novel glucagon product has not yet been approved by the FDA, there is currently only speculation regarding its potential market price. The manufacturer has stated it intends initially to match the current average wholesale price of the GEK auto-injector (5).

Comments

The novel solution technology employed for this product may have implications for use with future glucagon delivery designs such as a bihormonal artificial pancreas closed-loop system that delivers both insulin and glucagon (5). An additional liquid-stable glucagon analog formulation in development by Adocia may create future competition for the Xeris product, leading to subsequent lower costs to consumers.

Bottom Line

This shelf-stable, premixed auto-injector for the treatment of acute hypoglycemia has proven to be quicker and less complicated to administer by trained and untrained users alike, with a 99% success rate for full dose delivery (6). The Gvoke HypoPen auto-injector is equally efficacious compared to the currently available GEK for use in adults and children (5).

Acknowledgments

Duality of Interest

No potential conflicts of interest relevant to this article were reported.

  • © 2019 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See www.diabetesjournals.org/content/license for details.

References

  1. 1.↵
    1. Cryer PE,
    2. Davis SN,
    3. Shamoon H
    . Hypoglycemia in diabetes. Diabetes Care 2003;26:1902–1912
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Kedia N
    . Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach. Diabetes Metab Syndr Obes 2011;4:337–346
    OpenUrlPubMed
  3. 3.↵
    1. Wishart DS,
    2. Feunang YD,
    3. Guo AC, et al.
    DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 2018;46:D1074–D1082
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Newswanger B,
    2. Ammons S,
    3. Phadnis N, et al.
    Development of a highly stable, nonaqueous glucagon formulation for delivery via infusion pump systems. J Diabetes Sci Technol 2015;9:24–33
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Xeris Pharmaceuticals, Inc
    . Annual report pursuant to section 13 or 15 of the Securities Exchange Act of 1934. 6 March 2019. Available from www.xerispharma.com/images/xeris-annual-report-2018.pdf. Accessed 20 May 2019
  6. 6.↵
    1. Christiansen M,
    2. Cummins M,
    3. Prestrelski S,
    4. Junaidi K
    . A phase 3 comparison of a ready-to-use liquid glucagon rescue pen to glucagon emergency kit for the symptomatic relief of severe hypoglycemia. Poster presented at the Diabetes Technology Society’s Diabetes Technology Meeting, 8–10 November 2018, Bethesda, Md.
  7. 7.↵
    1. Bajpai S,
    2. Poehlmann J,
    3. Osumili B,
    4. Mitchell B,
    5. Valentine W
    . Nasal glucagon saves professional emergency medical (EM) costs versus intramuscular glucagon: a US based cost-offset model. Value Health 2018;21(Suppl. 1):S76
    OpenUrl
PreviousNext
Back to top
Clinical Diabetes: 37 (4)

In this Issue

October 2019, 37(4)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Clinical Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Gvoke HypoPen: An Auto-Injector Containing an Innovative, Liquid-Stable Glucagon Formulation for Use in Severe Acute Hypoglycemia
(Your Name) has forwarded a page to you from Clinical Diabetes
(Your Name) thought you would like to see this page from the Clinical Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Gvoke HypoPen: An Auto-Injector Containing an Innovative, Liquid-Stable Glucagon Formulation for Use in Severe Acute Hypoglycemia
Damianne Brand-Eubanks
Clinical Diabetes Oct 2019, 37 (4) 393-394; DOI: 10.2337/cd19-0040

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Gvoke HypoPen: An Auto-Injector Containing an Innovative, Liquid-Stable Glucagon Formulation for Use in Severe Acute Hypoglycemia
Damianne Brand-Eubanks
Clinical Diabetes Oct 2019, 37 (4) 393-394; DOI: 10.2337/cd19-0040
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Introduction
    • Indications
    • Mechanism of Action
    • Potential Advantages
    • Potential Disadvantages
    • Cost
    • Comments
    • Bottom Line
    • Acknowledgments
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Departments

  • Glycemic Control During Gender-Affirming Therapy in a Patient With Type 1 Diabetes
  • Good to Know: Nerve Damage and Diabetes
  • Community Primary Care Diabetes Pathway
Show more Departments

Clinical Pharmacology Update

  • Metformin Extended-Release Oral Solution
  • Bempedoic Acid: A Novel LDL Cholesterol–Lowering Agent
  • Plenity (Oral Superabsorbent Hydrogel)
Show more Clinical Pharmacology Update

Similar Articles

Navigate

  • Current Issue
  • Papers in Press
  • Abridged Standards of Care
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Diabetes Care
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Clinical Diabetes Print ISSN: 0891-8929, Online ISSN: 1945-4953.